A phase II clinical study focused on locally advanced bladder cancer and metastatic urothelial carcinoma that is HER2-positive (HER2 2+ and 3+) demonstrated the effectiveness of RC048-ADC treatment, with an evaluated overall response rate of 51.2%. This evidence concerns the gene ERBB2 and urinary bladder cancer.